Global Cord Blood Corporation (CO): Price and Financial Metrics
GET POWR RATINGS... FREE!
CO POWR Grades
- CO scores best on the Stability dimension, with a Stability rank ahead of 87.71% of US stocks.
- The strongest trend for CO is in Growth, which has been heading down over the past 176 days.
- CO ranks lowest in Growth; there it ranks in the 28th percentile.
CO Stock Summary
- The price/operating cash flow metric for GLOBAL CORD BLOOD CORP is higher than merely 3.22% of stocks in our set with a positive cash flow.
- For CO, its debt to operating expenses ratio is greater than that reported by only 4.1% of US equities we're observing.
- With a year-over-year growth in debt of -92.12%, GLOBAL CORD BLOOD CORP's debt growth rate surpasses merely 1.9% of about US stocks.
- Stocks with similar financial metrics, market capitalization, and price volatility to GLOBAL CORD BLOOD CORP are NTWK, UTMD, ALPP, CSTE, and TGEN.
- Visit CO's SEC page to see the company's official filings. To visit the company's web site, go to www.globalcordbloodcorp.com.
CO Stock Price Chart Interactive Chart >
CO Price/Volume Stats
| Current price | $2.99 | 52-week high | $5.50 |
| Prev. close | $2.22 | 52-week low | $2.03 |
| Day low | $2.21 | Volume | 9,284,800 |
| Day high | $3.32 | Avg. volume | 216,519 |
| 50-day MA | $2.41 | Dividend yield | N/A |
| 200-day MA | $3.32 | Market Cap | 363.44M |
Global Cord Blood Corporation (CO) Company Bio
Global Cord Blood Corporation provides umbilical cord blood storage and ancillary services in China. The company is based in Central, Hong Kong.
Latest CO News From Around the Web
Below are the latest news stories about GLOBAL CORD BLOOD CORP that investors may wish to consider to help them evaluate CO as an investment opportunity.
Global Cord Blood Corporation Files Annual Report on Form 20-FGlobal Cord Blood Corporation (NYSE: CO) ("GCBC" or the "Company"), China's leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing, and stem cell storage services, today announced that the Company filed its Annual Report on Form 20-F with the U.S. Securities and Exchange Commission. The filed Form 20-F includes audited financial statements for the fiscal year ended March 31, 2022. The Form 20-F can be accessed by visiting the U.S. Securities and Exchang |
Global Cord Blood Corporation Obtained Injunction Order Against Blue Ocean in respect of Purported EGMGlobal Cord Blood Corporation (NYSE: CO, "GCBC" or the "Company"), China's leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services, today announced that an injunction order (the "Order") previously obtained by the Company on June 15, 2022 from the Grand Court of the Cayman Islands (the "Court") against Blue Ocean Structure Investment Company Limited ("Blue Ocean") was officially issued by the Court on July 6, 2022. The Orde |
Global Cord Blood Corporation Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2022Global Cord Blood Corporation (NYSE: CO) ("GCBC" or the "Company"), China's leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services, today announced its unaudited financial results for the fourth quarter and full year of fiscal 2022, ended March 31, 2022. |
Global Cord Blood Corporation Announced Cellenkos Receives FDA Clearance of IND Application for CK0804 as Add on Therapy to Ruxolitinib for the Treatment of MyelofibrosisGlobal Cord Blood Corporation (NYSE: CO) ("GCBC" or the "Company"), China's leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services, is pleased to announce that Cellenkos, Inc. ("CLNK") recently announced that the U.S. Food and Drug Administration ("FDA") has cleared its Investigational New Drug ("IND") application to initiate a Phase 1b, open-label study of CK0804 as an add on therapy to ruxolitinib in patients with myelof |
Shareholders Led by Blue Ocean Announce Successful Results of Extraordinary General Meeting of Global Cord Blood CorporationNEW YORK, June 16, 2022--Blue Ocean Structure Investment Company Ltd., ("Blue Ocean") and shareholders representing over 75% of the outstanding shares of Global Cord Blood Corporation (the "Company" or "Global Cord") (NYSE: CO) today announced the successful approval of all resolutions at the Global Cord Extraordinary General Meeting of Shareholders ("EGM") held today. 104,369,577 shares out of 121,551,075 total outstanding shares of Global Cord voted in the EGM, which represents 85.86 percent o |
CO Price Returns
| 1-mo | N/A |
| 3-mo | 3.10% |
| 6-mo | -19.19% |
| 1-year | -36.11% |
| 3-year | -35.14% |
| 5-year | -73.30% |
| YTD | -28.64% |
| 2021 | 12.94% |
| 2020 | -25.80% |
| 2019 | -22.48% |
| 2018 | -34.53% |
| 2017 | 62.58% |
Continue Researching CO
Want to see what other sources are saying about Global Cord Blood Corp's financials and stock price? Try the links below:Global Cord Blood Corp (CO) Stock Price | Nasdaq
Global Cord Blood Corp (CO) Stock Quote, History and News - Yahoo Finance
Global Cord Blood Corp (CO) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...